768 related articles for article (PubMed ID: 32557382)
1. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Thaçi D; Deleuran M; Blauvelt A; Bissonnette R; de Bruin-Weller M; Hide M; Sher L; Hussain I; Chen Z; Khokhar FA; Beazley B; Ruddy M; Patel N; Graham NMH; Ardeleanu M; Shumel B
Am J Clin Dermatol; 2020 Aug; 21(4):567-577. PubMed ID: 32557382
[TBL] [Abstract][Full Text] [Related]
2. Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study.
Paller AS; Siegfried EC; Simpson EL; Cork MJ; Sidbury R; Chen IH; Khokhar FA; Xiao J; Dubost-Brama A; Bansal A
Am J Clin Dermatol; 2024 Jul; 25(4):655-668. PubMed ID: 38743155
[TBL] [Abstract][Full Text] [Related]
3. No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.
Blauvelt A; Wollenberg A; Eichenfield LF; Zhang H; Sierka D; Khokhar FA; Vakil J; Shabbir A; Marco AR; Cyr SL
Adv Ther; 2023 Jan; 40(1):367-380. PubMed ID: 36318387
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Blauvelt A; Teixeira HD; Simpson EL; Costanzo A; De Bruin-Weller M; Barbarot S; Prajapati VH; Lio P; Hu X; Wu T; Liu J; Ladizinski B; Chu AD; Eyerich K
JAMA Dermatol; 2021 Sep; 157(9):1047-1055. PubMed ID: 34347860
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis.
Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Chen Z; Thomas RB; Kosloski MP; Dubost-Brama A; Prescilla R; Bansal A; Levit NA
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2697-2719. PubMed ID: 37750994
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials.
Silverberg JI; Lynde CW; Abuabara K; Patruno C; de Benedetto A; Zhang H; Thomas RB; Bégo-Le-Bagousse G; Khokhar FA; Vakil J; Marco AR; Levit NA
Am J Clin Dermatol; 2023 May; 24(3):469-483. PubMed ID: 36808602
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials.
Paller AS; Silverberg JI; Cork MJ; Guttman-Yassky E; Lockshin B; Irvine AD; Kim MB; Kabashima K; Chen Z; Lu Y; Bansal A; Rossi AB; Shabbir A
JAMA Dermatol; 2023 Mar; 159(3):255-266. PubMed ID: 36723913
[TBL] [Abstract][Full Text] [Related]
8. Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.
Paller AS; Siegfried EC; Cork MJ; Wollenberg A; Arkwright PD; Gonzalez ME; Lockshin B; Chen Z; Bansal A; Levit NA; Prescilla R
Paediatr Drugs; 2023 Jan; 25(1):67-77. PubMed ID: 36529811
[TBL] [Abstract][Full Text] [Related]
9. Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials.
Stein Gold L; Thaçi D; Thyssen JP; Gooderham M; Laquer V; Moore A; Natalie CR; Zhao F; Meskimen E; Elmaraghy H; Montmayeur S; Gallo G; Jimenez G; de Bruin-Weller M
Am J Clin Dermatol; 2023 Jul; 24(4):595-607. PubMed ID: 37195407
[TBL] [Abstract][Full Text] [Related]
10. Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry.
Simpson EL; Lockshin B; Lee LW; Chen Z; Daoud M; Korotzer A
Dermatol Ther (Heidelb); 2024 Jan; 14(1):261-270. PubMed ID: 38175364
[TBL] [Abstract][Full Text] [Related]
11. Conjunctivitis in dupilumab clinical trials.
Akinlade B; Guttman-Yassky E; de Bruin-Weller M; Simpson EL; Blauvelt A; Cork MJ; Prens E; Asbell P; Akpek E; Corren J; Bachert C; Hirano I; Weyne J; Korotzer A; Chen Z; Hultsch T; Zhu X; Davis JD; Mannent L; Hamilton JD; Teper A; Staudinger H; Rizova E; Pirozzi G; Graham NMH; Shumel B; Ardeleanu M; Wollenberg A
Br J Dermatol; 2019 Sep; 181(3):459-473. PubMed ID: 30851191
[TBL] [Abstract][Full Text] [Related]
12. Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure.
Simpson EL; Silverberg JI; Nosbaum A; Winthrop K; Guttman-Yassky E; Hoffmeister KM; Egeberg A; Valdez H; Fan H; Farooqui SA; Chan G; Alderfer J; Romero W; Chittuluru K
Am J Clin Dermatol; 2024 Jul; 25(4):639-654. PubMed ID: 38888681
[TBL] [Abstract][Full Text] [Related]
13. Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis.
Eichenfield LF; Bieber T; Beck LA; Simpson EL; Thaçi D; de Bruin-Weller M; Deleuran M; Silverberg JI; Ferrandiz C; Fölster-Holst R; Chen Z; Graham NMH; Pirozzi G; Akinlade B; Yancopoulos GD; Ardeleanu M
Am J Clin Dermatol; 2019 Jun; 20(3):443-456. PubMed ID: 31066001
[TBL] [Abstract][Full Text] [Related]
14. Long-term, observational, real-world study of dupilumab for the treatment of moderate-to-severe atopic dermatitis: a 52-week single-center retrospective analysis in China.
Deng S; Wang H; Chen Q; Chen X; Song X; Chen S; Kong M; Song Z
Arch Dermatol Res; 2024 May; 316(6):304. PubMed ID: 38819652
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
Paller AS; Flohr C; Eichenfield LF; Irvine AD; Weisman J; Soung J; Pinto Correia A; Natalie CR; Rodriguez Capriles C; Pierce E; Reifeis S; Gontijo Lima R; Armengol Tubau C; Laquer V; Weidinger S
Dermatol Ther (Heidelb); 2023 Jul; 13(7):1517-1534. PubMed ID: 37318750
[TBL] [Abstract][Full Text] [Related]
16. Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis.
Paller AS; Siegfried EC; Cork MJ; Arkwright PD; Eichenfield LF; Ramien M; Khokhar FA; Chen Z; Zhang A; Cyr SL
Paediatr Drugs; 2024 Mar; 26(2):163-173. PubMed ID: 38267692
[TBL] [Abstract][Full Text] [Related]
17. Multicenter Canadian case series of pediatric patients less than 12 years of age with moderate-to-severe atopic dermatitis treated with dupilumab.
Martinez-Cabriales S; Marcoux D; Liy-Wong C; Prajapati VH; Sibbald C; Cunningham N; Lansang P; Tonkin R; Joseph M; Wong L; Spring S; Gavigan G; Ramien M
Pediatr Dermatol; 2024; 41(1):5-11. PubMed ID: 37906120
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study.
Merola JF; Chiou AS; During E; Costanzo A; Foley P; Alfalasi A; Gogate S; Pinter A; Dodiuk-Gad R; Simon D; Tauber M; Weller R; Pereyra-Rodriguez JJ; Ardeleanu M; Wu J; Ozturk ZE
Br J Dermatol; 2023 Nov; 189(6):685-694. PubMed ID: 37562034
[TBL] [Abstract][Full Text] [Related]
19. [Clinical observation on the efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis].
Li CY; Chen S; Qian WL; Yang L; Zheng Q; Chen AJ; Chen J; Huang K; Fang S; Wang P; Hu L; Liu XR; Zhao XQ; Tan N; Cai T
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Oct; 57(10):1590-1595. PubMed ID: 37859375
[TBL] [Abstract][Full Text] [Related]
20. Improvement of Pruritus and Efficacy in the Early Stage of Therapy with Upadacitinib, Abrocitinib, or Dupilumab in Chinese Patients with Moderate-to-Severe Atopic Dermatitis: Prospective, Cohort, Observational Study.
Huang D; Lu J; Tan F
Dermatitis; 2024; 35(1):77-83. PubMed ID: 37930745
[No Abstract] [Full Text] [Related]
[Next] [New Search]